To the Editor: In the study by Dr Kahn and colleagues,1 both the control and treatment groups were given incomplete Freund adjuvant (IFA), with the treatment group receiving viral antigen in addition to the adjuvant. The purpose of adjuvants is to increase the potency of vaccines, since particulate antigens alone are weak immunogens. Incomplete Freund adjuvant is a water-in-oil emulsion that may produce an immune response for as long as 6 months.2 It has been shown that IFA without antigen increases cytokine messenger RNA production of 6 interleukins (IL-1, IL-2, IL-4, IL-5, IL-6, and IL-13) in mice.3 Thus it appears that both the control and treatment groups in the study by Kahn et al were treated with an active and durable immunomodulating agent.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.